The American Academy of Dermatology (AAD) Annual Meeting returns March 27–31, bringing more than 275 sessions and a renewed focus on transformative science, clinical innovation, and crossdisciplinary collaboration.
Below is a curated selection of sessions offering particularly high scientific and clinical value for 2026.
📅 Friday, March 27 | 7:30–8:30 AM
📍 Bluebird 2E
Presented by Dermatologists in Industry, a non-profit association led by Indero’s Chief Medical and Scientific Officer, Dr. Jasmina Jankicevic, this session spotlights the dermatology-specific drug development ecosystem, from early discovery to regulatory approval. Panelists will share real-world insights into partnering across academia, private practice, and industry, and will outline evolving career pathways for dermatologists seeking roles in clinical development or medical affairs.
📅 Friday, March 27 | 9:00 AM–12:00 PM
📍 Bluebird 1A
This dynamic symposium highlights the “hot topics” identified directly by AAD registrants, offering a real‑time reflection of current clinical priorities. Faculty will spotlight recent trends, emerging evidence, and innovative therapies, ensuring each presentation remains dermatology‑focused, clinically practical, and immediately applicable to patient care.
📅 Friday, March 27 | 1:00–4:00 PM
📍 Bluebird 1B
A comprehensive overview of atopic dermatitis (AD) across pediatric and adult populations. Faculty will explore epidemiology, barrier dysfunction, immune dysregulation, itch pathways, emerging therapies, and the atopic march, linking mechanistic insights to treatment selection amid an expanding therapeutic landscape.
📅 Saturday, March 28 | 9:00 AM–12:00 PM
📍 Bluebird 1A
A deep dive into the growing role of Janus kinase (JAK) inhibition across inflammatory and immune-mediated skin diseases, including alopecia areata (AA), AD, psoriasis, vitiligo, prurigo nodularis, hidradenitis suppurativa (HS), and more. The session will outline clinical evidence and explore disease-specific safety considerations essential for individualized risk–benefit assessment.
📅 Saturday, March 28 | 1:00–4:00 PM
📍 Bluebird 1A
Facilitated by Dr. Emma Guttman, this session highlights how advances in immune pathway science are redefining treatment paradigms. Experts will discuss emerging targeted therapies informed by translational discoveries and review shared immunologic mechanisms across psoriasis, AD, HS, alopecia, vitiligo, acne, and rosacea.
📅 Sunday, March 29 | 8:00–9:00 AM
📍 Four Seasons 3
Expect fast paced pearls grounded in real-world data. Topics span psoriasis, hair loss, itch, skin cancer, oncodermatology, and emerging artificial intelligence (AI) applications, giving clinicians actionable updates for high-volume conditions.
📅 Sunday, March 29 | 1:00–4:00 PM
📍 Four Seasons 3
This session reviews the latest developments in oral and biologic psoriasis therapies, precision dermatology approaches, and strategies for managing challenging subtypes such as generalized pustular and palmoplantar psoriasis. Debates on lipid monitoring/statin initiation and IL-17 vs IL-23 inhibition add timely relevance to areas of ongoing clinical uncertainty.
📅 Monday, March 30 | 9:00–11:00 AM
📍 Mile High 1D
A focused exploration of diagnostically complex and quality of life limiting palmoplantar conditions. Faculty, including Indero’s Founder and Executive Chairman, Dr. Robert Bissonnette, will review presentations and management strategies for psoriasis, palmoplantar pustulosis (PPP), vitiligo, chronic hand eczema, periungual warts, and recurrent actinic keratoses.
📅 Monday, March 30 | 3:30–5:30 PM
📍 Mile High 4D
An in-depth review of chronic spontaneous urticaria (CSU) pathophysiology, disease burden, and evolving therapeutic options. The session will also highlight patient and physician reported outcome measures increasingly used to guide treatment evaluation and optimize management.
📅 Tuesday, March 31 | 10:15 AM–12:15 PM
📍 Four Seasons 1
A broad overview of cutting-edge updates across inflammatory diseases, pediatric dermatology, procedural dermatology, and cutaneous oncology. Expect highlights on emerging therapies for psoriasis, AD, vitiligo, alopecia, and HS, aligning with AAD 2026’s emphasis on innovation and clinical relevance.
Conclusion
AAD 2026 continues to expand its clinical and scientific depth, offering numerous opportunities for networking and professional development.
This curated selection reflects sessions with the strongest potential impact on patient care, therapeutic innovation, and translational progress in dermatology.
About the author
Sherry Lin is a Clinical Scientist at Indero, providing scientific and medical writing support across the clinical development lifecycle. With nearly a decade of experience in clinical research and the medical industry, Sherry brings expertise in scientific literature review, and clear, precise scientific communication.
